NeuroMab™ Anti-TREM2 BBB Shuttle Antibody(NRZP-1022-ZP2711)

Figure 1 shows the increased agonistic activity of Fc variant anti-TREM2 antibodies. Luciferase activity of Fc variant antibodies co-cultured with BWZ reporter cells and THP-1 cells at a ratio of 1:1 for 6 hours.

Figure 2 shows the increased agonistic activity of Fc variant anti-TREM2 antibodies. Luciferase activity after 6 hours of incubation with the Fc variant of an anti-TREM2 antibody.

Figure 3 shows C3b deposition induced by Fc variant anti-TREM2 antibodies. Fold change of C3b deposition on HEK expressing TREM2 cell line for AL2p Fc variants relative to human IgG1 isotype control antibody at 10 μg/mL.

Figure 4 shows C3b deposition induced by Fc variant anti-TREM2 antibodies. Fold change in C3b deposition of AL2p affinity matured variants with the listed Fc mutations relative to their parental IgG1 Fc variants.

Figure 5 shows the increased activity of soluble anti-TREM2 antibodies.

Figure 6 shows the increased activity of soluble anti-TREM2 antibodies.

Figure 7 shows sTREM2 secreted by primary human dendritic cells from donor 534 over 48 hours after incubation with anti-TREM2 or control antibody.

Figure 8 shows that there was no change in cell number after incubation of primary human dendritic cells from donor 534 with anti-TREM2 or control antibodies.

Figure 9 shows plasma sTREM2 as a percentage of baseline levels following a single injection of 15 mg/kg of the TREM2 antibodies AL2p-47 huIgG1, AL2p-47 huIgG1 ASPSEG, AL2p-58 huIgG1, or control huIgG1.

Figure 10 depicts increased viability (increased cellular ATP) after stimulation of primary human macrophages.

Figure 11 shows Western blot analysis of Dap12 phosphorylation in peritoneal macrophages of WT or TREM2 Bac-Tg mice treated with AL2p-58 huIgG1, AL2p-58 huIgG1 PSEG, or control huIgG1.